Drug Profile
Imatinib sublingual - Kedem Pharmaceuticals
Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Kedem Pharmaceuticals
- Class Amines; Anti-inflammatories; Antineoplastics; Antivirals; Benzamides; Eye disorder therapies; Piperazines; Pyridines; Pyrimidines; Small molecules
- Mechanism of Action Angiogenesis inhibitors; Bcr-abl tyrosine kinase inhibitors; Platelet-derived growth factor receptor antagonists; Signal transduction pathway inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Chronic myeloid leukaemia
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for clinical-Phase-Unknown development in Chronic-myeloid-leukaemia in USA (Sublingual)
- 12 Jan 2012 Clinical trials in Chronic myeloid leukaemia in USA (Sublingual)